Objectives: Tobacco use is undertreated in individuals with psychiatric and substance use disorders (SUDs), with concerns that quitting smoking may compromise recovery. We evaluated outcomes of a tobacco intervention among psychiatric patients with co-occurring SUDs. Methods: Data from 2 randomized tobacco treatment trials conducted in inpatient psychiatry were combined; analyses focused on the subsample with co-occurring SUDs (n ¼ 216). Usual care provided brief advice to quit and nicotine replacement therapy during the smoke-free hospitalization. The intervention, initiated during hospitalization and continued 6 months after hospitalization, was tailored to readiness to quit smoking, and added a computer-assisted intervention at baseline, and 3 and 6 months; brief counseling; and 10 weeks of nicotine replacement therapy after hospitalization. Outcomes were 7-day point prevalence abstinence from 3 to 12 months and past 30-day reports of alcohol and illicit drug use. Results: The sample consisted of 34% women, among which 36% were Caucasian, averaging 19 cigarettes/d prehospitalization; the groups were comparable at baseline. At 12 months, 22% of the intervention versus 11% of usual care participants were tobaccoabstinent (risk ratio 2.01, P ¼ 0.03). Past 30-day abstinence from alcohol/drugs did not differ by group (22%); however, successful quitters were less likely than continued smokers to report past 30-day cannabis (18% vs 42%) and alcohol (22% vs 58%) use (P < 0.05), with no difference in other drug use. Conclusions: Tobacco treatment in psychiatric patients with cooccurring SUDs was effective and did not adversely impact recovery.
F
or the clinician, a smoker with dual issues of mental illness and substance use disorders (SUDs) presents a hefty treatment challenge. Although the smoking prevalence in the general population has dropped to 18%, people with mental illness and SUD have 2 to 4-fold higher rates of smoking than the general population, and are estimated to consume nearly half of the cigarettes sold in the United States (Lasser et al., 2000; Grant et al., 2004 ; US Department of Health and Human Services, 2014) . In treatment settings, over half of patients smoke; methadone maintenance programs and inpatient psychiatry units generally have the highest rates, in the range of 75% to 95% (Kleber et al., 2007; Diaz et al., 2009) .
The morbidity and mortality ramifications are significant. Adults living with serious mental illness die on average 25 years earlier than other Americans, largely due to treatable medical conditions related to tobacco use such as heart disease, cancer, and cerebrovascular, respiratory, and lung diseases (Colton and Manderscheid, 2006; Parks et al., 2006) . Combined, 200 ,000 of the 520,000 premature deaths in the United States annually are estimated to occur among those with mental illness or SUDs (Schroeder and Morris, 2010) . Smoking causes more deaths and disease than alcohol and all other drugs combined (US Department of Health and Human Services, 2014) . This is true, even among individuals with heavy alcohol and drug use. Long-term drug abusers who smoke have 4 times the mortality risk of nonsmokers with drug abuse problems (Hser et al., 1994) . The negative consequences are not just additive, but multiplicative, in that the overall harms are greater than the sum of the parts (Bien and Burge, 1990) . For example, in a study of oral, laryngeal, esophageal, and liver cancer, alcohol and tobacco together had multiplicative effects on cancer progression (Pelucchi et al., 2006) .
The biopsychosocial consequences of smoking in those with mental illness or SUD go beyond the direct health effects. On an economic level, smoking can affect treatment and survival by using funds and effort to obtain cigarettes; in a study of smokers with schizophrenia, 27% of their median income was spent on cigarettes (Steinberg et al., 2004) . On a social level, smokers experience discrimination and stigma, which can add to stigma related to mental illness and/or SUD (Castaldelli-Maia et al., 2016) .
Primary psychiatric disorders also are adversely affected. In schizophrenia, smoking is associated with increased psychiatric symptoms, hospitalizations, and the need for higher medication doses (Ziedonis et al., 1994) . Tobacco withdrawal symptoms include anxiety and depression; in smoke-free treatment settings, the expression of anxiety and mood disorders in heavy smokers may appear amplified. When smokers hospitalized for mental illness are not treated for nicotine withdrawal, rates of leaving against medical advice are increased 2-fold (Prochaska et al., 2004a) . Further, independent association is well-documented between cigarette smoking and suicide; smoking cessation may mitigate the risk (Li et al., 2012) .
Despite the increased mortality, morbidity, co-occurrence, and biopsychosocial ramifications of cigarette smoking among those with mental illness and SUD, psychiatric and addiction treatment programs have traditionally overlooked tobacco as a treatment target, with concern that efforts to quit smoking may threaten mental health recovery or sobriety. In a survey by the American Association of Medical Colleges of more than 3000 physicians, 47% of psychiatrists thought patients had more immediate problems to address and 22% reported that cessation heightens other symptoms; psychiatrists were the least likely to treat tobacco relative to other medical specialties (American Association of Medical Colleges, 2007) . A review of 26 studies on smoking bans found that staff believe tobacco is important for self-medication, and smoking bans in psychiatric units would worsen symptoms and increase behavioral problems, though research has demonstrated otherwise (Lawn and Pols, 2005) . Currently, only 1 in 4 mental health treatment facilities in the United States offer services to quit smoking (SAMHSA, 2014) .
On the contrary, smokers with mental illness or SUD are just as motivated to quit smoking as the general population; among hospitalized smokers with mental illness, 65% were interested in quitting (Prochaska et al., 2006) . There is no evidence of worsening of clinical symptoms of unipolar depression, bipolar disorder, posttraumatic stress disorder, or schizophrenia with tobacco treatment . Furthermore, treatment of tobacco dependence is associated with a decreased likelihood of rehospitalization, and, in a metaanalysis of 19 studies, with an increased likelihood of sobriety among smokers in treatment for addictive disorders; notably, only 3 of these studies were in inpatient addiction treatment settings and none was conducted with smokers with co-occurring mental illness (Prochaska et al., 2004b) .
Current Tobacco Clinical Practice Guidelines recommend providing evidence-based tobacco cessation treatment to all smokers (Fiore, 2008) . The American Psychiatric Association identifies psychiatric hospitalization as an ideal opportunity to treat tobacco dependence; yet treatment of tobacco in psychiatry is not a regular practice (Kleber et al., 2007) . Outside of the data presented in this study, only 2 randomized tobacco treatment trials have been published with adult psychiatric inpatients, both studies conducted in Australia (Stockings et al., 2014; Metse et al., 2017) . In large part, dual diagnosis of mental illness and SUD is viewed as complicated.
Herein, we report on smoking cessation and recovery outcomes analyzing data on smokers with mental illness and SUD treated for tobacco use in 2 randomized controlled trials (Prochaska et al., 2014; Hickman et al., 2015) . The tobacco cessation interventions were initiated in inpatient psychiatry, and we focus here on the subsample dually diagnosed with mental illness and SUD.
METHODS

Setting
Data from 2 randomized controlled trials testing smoking cessation interventions in patients hospitalized for psychiatric treatment were combined. The studies (n ¼ 224 recruited 2006-2008, and n ¼ 100 recruited 2009-2010) had common inclusion/exclusion criteria measures and procedures (Prochaska et al., 2014; Hickman et al., 2015) . Psychiatric treatment was per protocol of the adult inpatient units.
Participants were recruited inhospital from four 100% smoke-free locked acute psychiatry units at 2 hospitals in the San Francisco Bay Area (1 academic and 1 public) and randomized to intervention or usual care. Intention to quit smoking was not required to participate as the intervention was informed by the Transtheoretical Model tailored to readiness to quit smoking.
Using medical records to identify positive smoking status, research staff worked with clinical staff to ask if a potential participant would like to hear about a smoking study; those interested were introduced to research staff who provided a greater description of the study and assessed eligibility for the trial. Inclusion criteria were: smoking at least 5 cigarettes daily before hospitalization, 18 years of age or older, and fluency in written and spoken English. Exclusion criteria were acute psychosis, hostility, or hypersomnolence that did not resolve sufficiently during hospitalization and contraindication for nicotine replacement therapy (NRT). Research staff fully reviewed the consent form with participants and assessed understanding of the purpose and potential risks and benefits of participation using a brief capacity to consent screening instrument (Hickman et al., 2011) .
Current analysis centered on participants with a SUD as defined by a positive drug abuse screening test (DAST) score !3 or positive alcohol use disorders identification test (AUDIT) score !8 at baseline (explanation of measures follows; see Fig. 1 for participant selection).
Measures
Screening Measures
The AUDIT is a 10-item scale covering 3 conceptual domains: alcohol intake (items 1-3), dependence (items 4-6), and adverse consequences (items 7-10). It was developed by the World Health Organization, and scores can range from 0 to 40, with a standard cut point of 8 (Reinert and Allen, 2007) . The DAST is originally a 28-item face-valid self-report measure using yes/no questions to identify problematic substance use; there is a 10-item version of the test (Skinner, 1982) . Studies in dual diagnosis populations reported that the AUDIT and DAST exhibited good psychometric properties, with internal consistency reliability coefficients in the mid90s (O'Hare et al., 2004; Reinert and Allen, 2007; Boschloo et al., 2010) . A study in psychiatric patients in India of the AUDIT and DAST used cut points of 8 and 3, and demonstrated strong psychometric properties (Carey et al., 2003) . Similar findings were reported in a 2010 study with depressed and anxious men (Boschloo et al., 2010) . A 2004 study of the AUDIT administered on patients with serious mental illness reported a sensitivity of 0.71, with specificity of 0.95 at the cut point of 8 (Carey et al., 2003; O'Hare et al., 2004; Boschloo et al., 2010) .
Sample Descriptive Measures
Tobacco use measures were cigarettes per day (CPD); the Fagerström Test of Cigarette Dependence (FTCD range 0-10; <5 indicating low, 5 moderate, and >5 high nicotine dependence), which includes time to first cigarette (Fagerstrom, 2012) ; and the Smoking Stage of Change scale, categorizing smokers at baseline into precontemplation (no intention to quit in the next 6 months), contemplation (intention to quit in the next 6 months), or preparation (intention to quit in the next 30 days with a past year 24-hour quit attempt) (Prochaska and DiClemente, 1983) .
Outcomes of Interest
Outcomes of interest were abstinence from tobacco, alcohol, and other drugs, and change in psychiatric symptom ratings. Tobacco abstinence was self-reported at 3, 6, and 12 months follow-up and validated with a breath sample tested for levels of carbon monoxide (CO) exposure over the past 24 hours, as measured by a Bedfont Smokerlyzer, where a value of 10 parts per million verified abstinence (Jarvis et al., 1987) . If someone was lost to follow-up or not able to confirm nonsmoking status in person, collateral contacts obtained at baseline including friends, family, and health professionals were called to verify use in the past 7 days. Collateral reports were validated with CO confirmation in a study of smokers with SUD (Patten et al., 2002) . In addition to smoking status, we assessed any alcohol/illicit drug use for the past 30 days at each follow-up using the Addiction Severity Index (ASI) (McLellan et al., 1992) . Lastly, the 24-item Behavior and Symptom Identification Scale (BASIS-24) was administered with scales for substance abuse, depression, self-harm, psychosis, emotional lability, and interpersonal relationships (Eisen et al., 2004) . The substance abuse subscore looks at a participants' urge to drink or use of drugs, and also possible problems resulting from alcohol and/or drug use. We cannot report on the full BASIS-24 score since self-harm was not assessed by phone posthospitalization.
Intervention
The overall aim of the 2 original studies was to test a Transtheoretical Model tailored, computer-assisted smoking cessation intervention with NRT posthospitalization against enhanced usual care. Usual care included brief advice to quit, NRTon the unit, and a quit smoking pamphlet. The intervention group received usual care plus the Transtheoretical Model stage tailored computer delivered intervention with printed report, stage-matched treatment manual, and on-unit individual cessation counseling. As part of standard care, participants in both conditions were offered NRT during their smoke-free hospitalization to manage nicotine withdrawal symptoms. In addition, participants randomized to intervention were offered a 10-week course of study-provided NRT patch, which they could elect to receive once ready to quit-available at the time of hospital discharge or anytime up to the 6-month follow-up assessment via mail or from the research offices. The 15 to 30-minute counseling for the intervention group provided motivational enhancement and stage-tailored strategies for managing temptations, considering the pros and cons of change (ie, decisional balance), and encouraging use of stage-matched processes of change. The intervention group at 3 and 6 months posthospitalization repeated the computer intervention, which stored their previous entries providing ipsative feedback on how they changed over time, recommending next steps toward FIGURE 1. Participant recruitment and randomization with smoking follow-up rates. Ã Data combined from 2 randomized controlled trials testing smoking cessation interventions in patients hospitalized for psychiatric treatment (n ¼ 224 and n ¼ 100) which had common inclusion/exclusion criteria measures and procedures (Hickman et al., 2015) . quitting smoking and maintaining abstinence. The intervention has been reported on previously (Prochaska et al., 2014; Hickman et al., 2015) . Internal Review Board approval was obtained by the respective institutions.
Analysis
Baseline variables were summarized and compared for intervention and usual care groups. Pearson chi-square tests were used to compare sex, ethnicity, hospitalization status (voluntary vs not), insurance status, diagnosis, past 30-day alcohol/drug use, and smoking stage of change by treatment groups. Two-sample t tests were used to compare age, CPD, FTCD, AUDIT, and DAST-10 scores.
To examine the primary outcome of interest, we compared smoking status between treatment groups at 12 months using Pearson chi-square tests and by calculating relative risk. Further, we estimated and tested a logistic regression model using a generalized estimating equation (GEE) model (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.) to examine abstinence versus smoking status at each follow-up point (3, 6, and 12 months). Secondary outcomes of interest compared among treatment groups were change in the BASIS-24 substance abuse subscore and past 30-day drug or alcohol use at 12 months using t tests. Finally, we compared use of alcohol and other drugs between those who were smoking and those who were not smoking at 12 months using Pearson chi-square tests. All analyses were 2-sided and done at the a ¼ 0.05 level.
RESULTS
Of the 324 original participants, 216 (67%) were determined to have a SUD based on our criteria; 111 were randomized to the usual care group and 105 to the intervention group (see Fig. 1 ).
Baseline Characteristics
At baseline, there were no major differences found between intervention and usual care groups on all demographic, psychiatric, and tobacco-related variables of interest (Table 1 ). The sample was 66% men and 36% non-Hispanic white with a mean age of 39 years (SD ¼ 13); 31% of the sample was hospitalized voluntarily. Insurance status was: 17% self-pay, 30% private insurance, 53% Medicare/MediCal. Diagnoses were: 44% unipolar depression, 20% bipolar depression, 24% psychotic disorder, and 12% other. Smoking stage of change was 33% precontemplation, 47% contemplation, and 20% preparation. The mean number of cigarettes smoked per day before hospitalization was 19 (SD ¼ 12) and the mean FTCD score was 5.0 (SD ¼ 2.3), indicating moderate nicotine dependence; 43% were classified as highly dependent (FTCD >5). Nearly all participants (94%) reported alcohol or illicit drug use in the 30 days before hospitalization. Participants randomized to the usual care and treatment groups differed only in past 30-day reported use of cocaine and amphetamines, in both cases reported more frequently by participants randomized to the treatment than in the usual care group.
Primary and Secondary Outcomes
At 12 months, there was a significant difference in smoking status by treatment group: 22% of the treatment group was not smoking compared with 11% of the usual care group (risk ratio [RR] 2.01, 95% confidence interval [CI] 1.05-3.83) ( Table 2) . In a GEE model testing the effect over time, tobacco abstinence rates over 12 months differed significantly by treatment condition (odds ratio [OR] 2.30, 95% CI 1.08-4.90, P < 0.05) (Fig. 2) .
Comparing treatment and usual care groups, there was no significant difference in reported past 30-day use of any drug (65% vs 68%), alcohol (57% vs 47%), or combined alcohol and drugs (81% vs 76%) at 12 months (Table 2) . Further, by treatment condition, change in BASIS-24 scale scores did not differ by treatment group: substance abuse (t ¼ 0.01, P ¼ 0.99), depression/functioning (t ¼ 0.81, P ¼ 0.42), interpersonal relationships (t ¼ À0.59, P ¼ 0.55), emotional lability (t ¼ 0.78, P ¼ 0.44), and psychosis (t ¼ 0.58, P ¼ 0.56).
At 12 months follow-up, examined by smoking status, those who quit smoking compared with continued smokers were less likely to report past 30-day alcohol (22% vs 58%; x 2 ¼ 10.02, P ¼ 0.002; Fig. 3 ) and cannabis use (42% vs 18%; x 2 ¼ 4.47, P ¼ 0.027). There was no difference in reported past 30-day use of other drugs on the ASI by tobacco quit status at 12 months. Further, there was no significant difference in changes on the BASIS-24 scale scores when comparing those quit smoking to those who did not.
DISCUSSION
A tobacco cessation treatment initiated during inpatient psychiatric hospitalization among smokers with co-occurring mental illness and SUD was successful in doubling confirmed smoking abstinence rates at 12 months follow-up when compared with usual care. Further, there was no indication of harm to substance use recovery associated with the tobacco cessation treatment. Instead, irrespective of treatment group, those who quit smoking were found, at 12 months follow-up, to have half the rates of past 30-day alcohol and cannabis use, relative to those who continued smoking.
Although the outcome differences in substance use are associative and not necessarily causative, recent models, both at the addiction neurocircuitry level and cell/molecular biology levels, suggest the presence of the Gateway Hypothesis and the Common Liability Model. First, the Gateway Hypothesis posits that use of nicotine and alcohol can increase the risk to use other drugs. Similarly, the common liability model asserts that genetic, familial, and individual traits make one liable for multiple substances. It is thought that since different drugs are used together, they can in turn be treated together (Kandel and Kandel, 2015) . The comorbidity of tobacco and other substance use, both socially and biologically, is impetus to treat both simultaneously so that there is additional benefit towards abstinence of each substance.
A smoke-free hospitalization provides a unique window of opportunity for addressing tobacco use in smokers with mental illness and SUD. Yet, the reality is that quitting smoking is not the presenting acute issue. In our sample, only 1 in 5 participants at baseline expressed intention to quit smoking in the next 30 days. Rather than requiring motivation to quit, and effectively excluding 80% of hospitalized smokers, we utilized a treatment approach that was tailored to motivation or stage of change for quitting smoking. Our piloting of the intervention indicated acceptability and appreciation of the approach, which did not require action to participate, but rather provided support and encouragement over time out to 6 months posthospitalization . Over time, quit rates rose to 22% at 12 months. The increase in quit rates over a year is a unique feature of a stage-based intervention. Stage-tailored interventions allow smokers not initially intending to quit to be supported through the process of quitting over time (Prochaska and DiClemente, 1983) . Hospital-based smoking cessation programs not directed at psychiatric patients have concluded that posthospitalization contact is associated with better quit rates (Rigotti et al., 2012) ; the Joint Commission Tobacco Treatment Measures have been updated to include a measure for post discharge contact with a smoker within 1 month of hospital discharge (Fiore et al., 2012) . Implementing the tobacco measure set for Joint Commission quality reporting could have major benefits for public health, through systematic identification, advice, and follow-up with hospitalized smokers. In the absence of a formal and extended intervention, even the most basic advice and a quitline referral is recommended (Fiore, 2008) ; in the current study, we observed a quit rate of 11% at 12 months in the enhanced usual care group, suggesting a low-intensity intervention was helpful to many patients.
Recruitment and retention rates were high, and a diagnostically and demographically diverse sample was enrolled, enhancing generalizability of the study findings. The study, however, was limited to 1 geographic region, the San Francisco Bay Area, where smoking rates are lower than the national average and there are more public restrictions on smoking. Whereas the tobacco abstinence outcomes were bioconfirmed when possible, the substance use measures were self-reported. Non-nicotine substance use was not a target of the smoking cessation intervention, and there is no reason to expect differential bias in self-reporting by condition.
This manuscript pulls from 2 trials with common procedures to complete an analysis on a subsample of those with co-occurring SUDs. We assume that with the common procedures, measures, and criteria that the data are similar. Despite the fact that the sample size increases from the combination of the data, there may be situations in which there are still too few responses. For example, although cannabis and alcohol use were fairly prevalent, there may not be enough power to detect differences in other drug use with smoking status.
A related limitation is that the trials were not designed to evaluate the specific question at hand. To our knowledge, this is the first study with randomized treatment groups to report on tobacco cessation outcomes among dually diagnosed smokers recruited from acute inpatient psychiatry settings. There are only 2 additional randomized controlled trials with adult psychiatric inpatients, both conducted in Australia (Stockings et al., 2014; Metse et al., 2017) . Both found short-term effects on abstinence that were not sustained, though reductions in smoking were reported; about 1 in 5 participants in the samples were identified with substance-related disorders. There are limited data on treating tobacco use and dependence in those with acute mental illness, and especially in those who are dually diagnosed. Further research to inform best practices is warranted.
Another limitation is that whereas changes in substance use and general psychiatric symptoms were measured, mental health diagnoses were not reassessed at 12 months. The BASIS-24 scales are of interest as they are domains that clinicians may be concerned about decompensating with tobacco treatment, and the results support the literature that these mental health outcomes are not adversely affected by tobacco treatment.
The findings support recommendations to treat tobacco use in clients with co-occurring mental illness and SUDs. Tobacco use disorders account for heavily increased mortality and morbidity among patients with mental illness, and outcomes are worse in those who have SUDs. It is imperative, and consistent with clinical practice guidelines, to offer advice and help to all patients who smoke. Not providing tobacco treatment goes against quality standards of care. Future treatments may look to address alcohol, tobacco, and other drugs in 1 integrated intervention, given the high rate of tobacco and SUD disorders among persons with mental illness. Combined treatment could lead to comprehensive care for a group at great risk of smoking-related morbidity and mortality.
